Subscribe
shutterstock_309001163_bill_perry
Bill Perry / Shutterstock.com
21 January 2021Americas

Federal Circuit agrees with PTAB in optical patent appeal

The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board (PTAB) which centered on the validity of a patent for an ophthalmic illuminator.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Allergan and tribe claim PTAB can’t decide on Restasis patents
13 March 2018   Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.
Americas
AbbVie Humira patent invalidated by PTAB
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Allergan and tribe claim PTAB can’t decide on Restasis patents
13 March 2018   Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.
Americas
AbbVie Humira patent invalidated by PTAB
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.

More on this story

Americas
Allergan and tribe claim PTAB can’t decide on Restasis patents
13 March 2018   Allergan and the Saint Regis Mohawk Tribe have argued that the Patent Trial and Appeal Board doesn’t have the jurisdiction to decide on the validity of patents concerning a dry-eye treatment while its recent decision is being appealed.
Americas
AbbVie Humira patent invalidated by PTAB
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.

More features

Weight-loss clinic hits back at Novo Nordisk’s Ozempic TM allegations
Eisai and Merck shield blockbuster cancer drug from generic challenge
Fed Circ refuses to stay Novartis feud with MSN over Entresto
Moderna entities must face infringement suits, UPC rules
Baker McKenzie adds London partner with ‘enviable’ expertise
‘Keep calm and carry on’: UK+ regime stays post-Brexit
As AI shakes up pharma and biotech, can patent law keep up?
UK court clears the way for Amgen and Samsung to launch biosimilars